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The expression of 11β-hydroxysteroid
dehydrogenase type 1 is increased in
experimental periodontitis in rats
Takaya Nakata1, Makoto Umeda2, Hiroaki Masuzaki3 and Hirofumi Sawai4*
Abstract
Background: The involvement of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which converts inactive
glucocorticoids into active glucocorticoids intracellularly, in metabolic diseases and chronic inflammatory diseases
has been elucidated. We recently reported that an increase in 11β-HSD1 expression was associated with chronic
periodontitis in humans irrespective of obesity. To further clarify the role of 11β-HSD1 in chronic periodontitis, the
expression of 11β-HSD1 was investigated in experimental periodontitis model in rats.
Methods: Experimental periodontitis was induced by silk ligature of left maxillary second molars of 7-week-old male
Wistar rats, and periodontal tissues were collected at day 3. The expression of 11β-HSD1, 11β-HSD2, and TNFα mRNA
was examined using real time reverse transcription-polymerase chain reaction. The expression of TNFα was used as an
indicator of inflammation. Thus, the rats in which the levels of TNFα mRNA were increased in the ligature-induced
periodontitis compared with the control were analysed.
Results: The findings demonstrated that the expression of 11β-HSD1 mRNA was significantly increased in experimental
periodontitis compared with the control. The increase in the levels of 11β-HSD1 mRNA in the ligature-induced
periodontitis compared with the control was positively correlated with that of TNFα mRNA. On the other hand, the
expression of 11β-HSD2 mRNA, which inactivates glucocorticoids, was slightly decreased in experimental periodontitis.
Therefore, the ratio of 11β-HSD1 versus 11β-HSD2 mRNA was significantly higher in experimental periodontitis than in
the control.
Conclusions: These results suggest that the increased expression of 11β-HSD1, which would result in the increased
levels of intracellular glucocorticoids, may play a role in the pathophysiology of experimental periodontitis.
Keywords: 11β-Hydroxysteroid dehydrogenase type 1, Glucocorticoids, Chronic periodontitis, Experimental periodontitis,
Inflammation
Background
The involvement of cortisol, a major glucocorticoid
hormone in humans, in chronic periodontitis has been
investigated. Serum and salivary cortisol levels were re-
ported to be correlated with measures of chronic peri-
odontitis [1–5]. In animal experiments, ligature-induced
periodontitis was more severe in hypothalamic-pituitary-
adrenal (HPA) high-responding Fischer 344 rats than in
MHC-identical but HPA low-responding Lewis rats.
Treatment with RU 486, a glucocorticoid receptor antag-
onist, reduced experimental periodontitis in Fischer 344
rats, suggesting that the increased glucocorticoids play a
role in experimental periodontitis [6–8]. However, the
mechanism by which the levels of glucocorticoids are in-
creased and the role of the increased glucocorticoids in
chronic periodontitis remain to be determined.
11β-hydroxysteroid dehydrogenases, one of the many
enzymes involved in the metabolism of glucocorticoids,
catalyze the intracellular conversion between active (corti-
sol in humans and corticosterone in rodents) and inactive
(cortisone in humans and 11-dehydrocorticosterone in
rodents) glucocorticoids [9–12]. Generally, 11β-HSD1
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activates and 11β-hydroxysteroid dehydrogenase type 2
(11β-HSD2) inactivates glucocorticoids. It was reported
that the expression of 11β-HSD1 was increased in adipo-
cytes, especially in visceral fat, of patients with metabolic
diseases, which suggests that 11β-HSD1 plays a role in
the pathogenesis of metabolic diseases [13–15]. Animal
studies supported this notion. 11β-HSD1-deficient mice
showed attenuated glucocorticoid-inducible responses
and resisted hyperglycemia on obesity or stress [16],
whereas transgenic mice overexpressing 11β-HSD1 select-
ively in adipose tissue developed visceral obesity that was
exaggerated by a high-fat diet [17, 18]. Furthermore,
several 11β-HSD1 inhibitors were reported to ameliorate
metabolic diseases in mice [19, 20]. Currently, several
11β-HSD1 inhibitors are being developed for the treat-
ment of metabolic diseases, especially type 2 diabetes
mellitus [21–24].
Since obesity, as well as metabolic diseases, can be
regarded as chronic inflammation of adipose tissue [25, 26],
the involvement of 11β-HSD1 in other chronic inflamma-
tory diseases has been investigated. The increased expres-
sion of 11β-HSD1 was demonstrated in inflammatory
bowel diseases and rheumatoid arthritis [27–30], suggesting
that the increased 11β-HSD1 plays a role in chronic in-
flammation. We recently investigated the expression of
11β-HSD1 in periodontal tissues from patients with
chronic periodontitis, and reported that the expression
of 11β-HSD1, as well as the ratio of 11β-HSD1 versus
11β-HSD2, was significantly higher in chronic periodon-
titis than in the control irrespective of obesity [31]. In this
study, to further clarify the role of 11β-HSD1 in chronic
periodontitis, the expression of 11β-HSD1 was investi-
gated in ligature-induced experimental periodontitis in
rats.
Methods
Animals
Fifty six-week-old male Wistar rats were purchased from
Shimizu Laboratory Supplies (Kyoto, Japan) and were
maintained under specific pathogen-free conditions with
food and distilled water at Osaka Dental University Ani-
mal Care. The experimental protocol was approved by
the Committee for Animal Experiments of Osaka Dental
University (#14-09001), and experimental procedures
were performed in accordance with the Guidelines for
Animal Experiments of Osaka Dental University.
Experimental periodontitis
Experimental periodontitis was induced as described with
modifications [32]. Experiments were started at 7 weeks of
age. General anesthesia was induced with inhalation of
isoflurane (Wako Pure Chemical Industries, Osaka, Japan)
and intraperitoneal injections of pentobarbital (Kyoritsu
Seiyaku Corporation, Tokyo, Japan) at 0.3 mg/kg body
weight. Silk threads (5-0 Nescosuture, Alfresa Pharma
Corporation, Osaka, Japan) were ligated around the cer-
vix of the left maxillary second molars to induce experi-
mental periodontitis. The right maxillary second molars
were used as the control. Three days after the ligation,
rats were euthanized with an overdose of isoflurane and
pentobarbital.
Micro-CT analysis
Images of the excised maxillary bones were analysed using
a micro-CT scanner, SMX-130CT (Shimadzu Corporation,
Kyoto, Japan). The micro-CT parameters were set as
follows: image pixel size, 512 × 512; voltage, 40 kV; beam
current, 40 μA; view number, 1200; scaling coefficient,
10. Three dimensional images were generated using
VGStudio MAX 1.2.1 software (Volume Graphics, GmbH,
Germany).
RNA extraction
Periodontal tissues around the right and left maxillary
second molars (for the control and periodontitis group,
respectively) were excised, and then homogenized in 1
ml of TRIzol Reagent (Invitrogen, Carlsbad, CA, USA).
After the addition of 0.2 ml chloroform, the mixture was
centrifuged at 12,000 g for 15 min at 4 °C. The aqueous
phase was transferred to a new tube and 0.5 ml of isopro-
pyl alcohol was added. After centrifugation at 10,000 g for
10 min at 4 °C, the RNA precipitate was washed with 1 ml
of 75 % ethanol and centrifuged at 7500 g for 5 min at
4 °C. Then the RNA precipitate was air-dried and dis-
solved in RNase-free water. For determination of RNA
concentration, the absorbance at 260 nm was measured
using a spectrophotometer, SmartSpec 3000 (Bio-Rad,
Hercules, CA, USA).
Real time reverse transcription (RT)-polymerase chain
reaction (PCR)
As probes for PCR, TaqMan Gene Expression Assays
for rat 11β-HSD1 (#Rn00567167_m1), rat 11β-HSD2
(#Rn00492539_m1), rat TNFα (#Rn99999017_m1), and
rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(#Rn01775763_g1) were purchased from Applied Biosys-
tems (Foster City, CA, USA). RT-PCR was performed
using TaqMan RNA-to-CT 1-Step Kit and StepOnePlus
Real Time PCR System (Applied Biosystems, Foster City,
CA, USA). Each template (20 ng RNA) was mixed with 1
μl of probe, 0.5 μl of RT Enzyme Mix, 10 μl of RT-PCR
Mix, and Nuclease-free water was added so that the total
volume of the mixture should be 20 μl. The mixture was
incubated for 15 min at 48 °C for reverse transcription,
followed by incubation for 10 min at 95 °C for inactivation
of reverse transcriptase and activation of DNA poly-
merase. For PCR, the mixture was incubated for 15 s at
95 °C for denaturing and then for 1 min at 60 °C for
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annealing/extension for 50 cycles. The values of 11β-
HSD1, 11β-HSD2, and TNFα mRNA relative to GAPDH
mRNA were calculated in each sample.
Histological examinations
Another set of experiments was performed for histological
examinations. After euthanasia, the rats were perfused
with 10 % formaldehyde neutral buffer solution (Sigma-
Aldrich, St. Louis, MO, USA). Then the maxillary bones
were excised, and fixed in 10 % formaldehyde neutral
buffer solution at 4 °C for 3 days. The bones were dec-
alcified in a rapid decalcification solution, K-CX (Falma,
Tokyo, Japan), at 4 °C for 24 h, followed by conventional
dehydration and paraffin embedding. After cutting into 5
μm-thick sections, the specimens were deparaffinized and
then stained with hematoxylin-eosin (HE) or immuno-
stained with either anti-11β-HSD1 antibody (Bioss,
Woburn, MA, USA) or anti-11β-HSD2 antibody (Santa
Cruz Biotechnology, Dallas, TX, USA) using Envision +
kit/HRP (DAB) (Dako, Glostrup, Denmark). Images were
obtained using an all-in-one microscope, BZ-9000
(Keyence, Osaka, Japan).
Statistical analyses
The comparison between the control and the periodon-
titis group was assessed by paired t-test. The correlation
between the increase in the levels of 11β-HSD1 mRNA
and that of TNFα mRNA was assessed by Pearson’s
correlation analysis using SPSS software version 21.0
(IBM, Armonk, NY, USA).
Fig. 1 Micro-CT scan of maxillary bones on the palatal side. a Control.
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Fig. 2 The expression of 11β-HSD1 mRNA is increased in the
ligature-induced periodontitis compared with the control. a The
values of 11β-HSD1 mRNA relative to GAPDH mRNA. b The values
of 11β-HSD2 mRNA relative to GAPDH mRNA. c The ratio of 11β-HSD1
versus 11β-HSD2 mRNA. Values are expressed as mean + standard
deviation (n = 16)
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Results
Experimental periodontitis was induced by ligature place-
ment, and alveolar bone loss due to ligature-induced peri-
odontitis was observed after 2 weeks (Fig. 1).
To investigate the involvement of 11β-HSD1 in experi-
mental periodontitis, the expression of 11β-HSD1, as
well as 11β-HSD2 mRNA, in periodontal tissues was
analysed by the real time RT-PCR method. The expression
of TNFα mRNA in periodontal tissues was concurrently
examined to confirm the induction of periodontitis by
ligature placement. Thus, the data of rats (n = 16) in which
the levels of TNFα mRNA were increased more than 1.4-
fold in the ligature-induced periodontitis compared with
the control were analysed. The levels of 11β-HSD1 mRNA
were significantly higher in periodontal tissues around the
left maxillary second molars than in those around the
right ones (Fig. 2a), whereas the levels of 11β-HSD2
mRNA were slightly, but not significantly, lower in the
former than in the latter (Fig. 2b). Therefore, the ratio
of 11β-HSD1 versus 11β-HSD2 mRNA was significantly
higher in the former than in the latter (Fig. 2c), which
is consistent with the results we recently reported using
human periodontal tissues.
Fig. 3 Positive correlation between the increase in the levels of
11β-HSD1 mRNA and that of TNFα mRNA in the ligature-induced
periodontitis compared with the control. ΔHSD1: subtraction of
the values of 11β-HSD1 mRNA in the control from those in the
ligature-induced periodontitis. ΔTNFα: subtraction of the values of
TNFα mRNA in the control from those in the
ligature-induced periodontitis
Fig. 4 Histological examination of 11β-HSD1 and 11β-HSD2 expression (at lower magnification). a, b HE staining. c, d Immunostaining with
anti-11β-HSD1 antibody. e, f Immunostaining with anti-11β-HSD2 antibody. a, c, e Control. b, d, f Ligature-induced periodontitis
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The increase in 11β-HSD1 mRNA in the ligature-
induced periodontitis compared with the control was
positively correlated with that in TNFα mRNA (p = 0.000
by significance testing of Pearson’s correlation coefficient)
(Fig. 3).
Histological examinations revealed that the expression
of 11β-HSD1 protein was increased in the ligature-
induced periodontitis, especially in the infiltrating
neutrophils in gingival lamina propria, compared with the
control (Figs. 4 and 5), which is in accordance with a recent
report demonstrating that 11β-HSD1 is highly expressed in
neutrophils [33]. The expression of 11β-HSD2 protein
was not apparently different between the control and
ligature-induced periodontitis.
Discussion
The close relationship between increased glucocorticoids
and chronic periodontitis has been reported. Since glu-
cocorticoids are increased during stress due to activation
of the HPA axis, several studies have reported that
chronic periodontitis is associated with stress [1, 2, 5]. In
contrast, we have recently reported that human chronic
periodontitis is associated with the increased expression
of 11β-HSD1, as well as the increased ratio of 11β-HSD1
versus 11β-HSD2 mRNA, which would result in the in-
creased levels of intracellular glucocorticoids [31]. In this
study, we demonstrated that the expression of 11β-HSD1,
as well as the ratio of 11β-HSD1 versus 11β-HSD2
mRNA, is increased in ligature-induced periodontitis in
rats. These results suggest that the increased intracellular
glucocorticoids may play a role in the pathogenesis of
chronic periodontitis independent of the HPA axis.
11β-HSD1 has been reported to be involved in meta-
bolic diseases, including obesity [13–15]. However, we
recently reported that increases in 11β-HSD1 mRNA, as
well as the ratio of 11β-HSD1 versus 11β-HSD2 mRNA,
were associated with chronic periodontitis, irrespective
of obesity in human subjects [31]. Since obesity, as well
as metabolic diseases, can be regarded as chronic inflam-
mation of adipose tissue [25, 26], and the increased expres-
sion of 11β-HSD1 has been demonstrated in chronic
inflammatory diseases such as inflammatory bowel diseases
and rheumatoid arthritis [27–30], these results suggest
that the increased 11β-HSD1 plays a role in chronic
Fig. 5 Histological examination of 11β-HSD1 and 11β-HSD2 expression (at higher magnification). a, b HE staining. c, d Immunostaining with
anti-11β-HSD1 antibody. e, f Immunostaining with anti-11β-HSD2 antibody. a, c, e Control. b, d, f Ligature-induced periodontitis. Some of the
infiltrating neutrophils, which are immunostained with anti-11β-HSD1 antibody, are indicated by the arrows
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inflammation. The increased expression of 11β-HSD1 in
chronic periodontitis in human subjects, as well as in
ligature-induced periodontitis in rats, seems to be in
accordance with this notion.
The precise role of the increased 11β-HSD1 in chronic
inflammation remains to be determined. Although gluco-
corticoids have strong anti-inflammatory effects [34]
pro-inflammatory effects of glucocorticoids have been
reported, especially in chronic inflammation [12, 30].
Furthermore, the pro-inflammatory role of 11β-HSD1
have been demonstrated [35, 36]. Thus, overexpression
of 11β-HSD1 augmented TNFα-induced iNOS, IL-6, and
MCP-1 expression, whereas 11β-HSD1 inhibitors at-
tenuated TNFα-induced NF-kB and MAPK signaling
pathways. In this study, the increase in the levels of
11β-HSD1 mRNA was proportional to that of TNFα
mRNA, indicating the extent of inflammation (Fig. 3),
which is consistent with the pro-inflammatory role of
11β-HSD1 and glucocorticoids. However, the causal re-
lationship between the increased 11β-HSD1 expression
and chronic inflammation, including chronic periodontitis,
needs to be determined using specific 11β-HSD1 inhibitors
or gene knockout animals.
Conclusions
We demonstrated for the first time that, to the best of
our knowledge, the expression of 11β-HSD1 mRNA is
increased in experimental periodontitis in animals. This
is in agreement with our recent report that the expres-
sion of 11β-HSD1 is increased in chronic periodontitis
in human subjects irrespective of obesity, suggesting that
the increased expression of 11β-HSD1, which would re-
sult in in the increased levels of intracellular glucocorti-
coids, may play a role in the pathogenesis of chronic
periodontitis independent of the HPA axis. Further in-
vestigation is required to elucidate the precise role of
11β-HSD1 in chronic periodontitis.
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